| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human TFPI-C-His-Avi protein was developed from hek293 and has a target region of C-His-Avi. For use in research applications. |
| Conjugation: |
Biotin |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: |
Upon receipt centrifuge vial to ensure maximal product extraction, recommended: 20sec, 5K RPM |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). |
| Gene Symbol: |
TFPI |
| Gene ID: |
7035 |
| Uniprot ID: |
TFPI1_HUMAN |
| Immunogen Region: |
Asp29-Lys282 |
| Immunogen: |
DNA sequence encoding Human TFPI including a C-His-Avi tag was expressed in HEK293 Cells. The recombinant protein was then biotinylated site specific using the AVItag biotinylation technology. |
| Post Translational Modifications | O-glycosylated. |
| Function | Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma. |
| Protein Name | Tissue Factor Pathway InhibitorTfpiExtrinsic Pathway InhibitorEpiLipoprotein-Associated Coagulation InhibitorLaci |
| Database Links | Reactome: R-HSA-140834 |
| Cellular Localisation | Isoform Alpha: SecretedIsoform Beta: Microsome MembraneLipid-AnchorGpi-Anchor |
| Alternative Protein Names | Tissue Factor Pathway Inhibitor proteinTfpi proteinExtrinsic Pathway Inhibitor proteinEpi proteinLipoprotein-Associated Coagulation Inhibitor proteinLaci proteinTFPI proteinLACI proteinTFPI1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
